Vaginal Estradiol Cost in District of Columbia 2026

What Vaginal Estradiol Actually Costs in DC Right Now

The sticker price and the real out-of-pocket price are very different numbers. Brand-name estradiol cream (Estrace 0.01%) carries a manufacturer list price of roughly $280 per month in 2026. Retail cash prices across DC pharmacies average around $120 per month once discount cards are applied. Compounded versions from a licensed 503A pharmacy can drop that figure to near $0, $40 per month depending on the compounding pharmacy's fee structure and whether a membership telehealth platform covers the dispensing cost.

Why the List Price and Street Price Diverge So Much

Pharmacy benefit managers negotiate rebates with brand manufacturers that never show up on the shelf tag. Discount aggregators like GoodRx pull from a separate contract network. The FDA notes that list prices are set by manufacturers and bear little relationship to patient-level cost after rebates and coupons are applied. Estrace (estradiol vaginal cream) full prescribing information is on file with the FDA.

A 2022 analysis in JAMA Internal Medicine found that for many hormone drugs, the cash price with a discount card was lower than the commercially insured copay at the same pharmacy. DC patients should always run a GoodRx or RxSaver check before paying an insurance copay. [1]

Dose Form Matters for Price

The three dominant dose forms, cream, ring, and vaginal tablet/insert, have meaningfully different price points.

• Estrace vaginal cream 0.01% (42.5 g tube): list ~$275, $290; cash with coupon ~$100, $130.
• Estring vaginal ring (releases 7.5 mcg/day for 90 days): list ~$350, $380 per ring; cash ~$180, $220. One ring lasts three months, so monthly cost is ~$60, $75 at cash price.
• Vagifem / Yuvafem 10 mcg vaginal tablet: list ~$250 for an 18-count box (roughly one month); cash ~$90, $120.

The Cochrane review of local estrogen for genitourinary syndrome of menopause (GSM), which pooled data from 30 randomized trials, found all three dose forms comparably effective for vaginal dryness and dyspareunia, meaning cost and patient preference should drive dose-form selection. [2]

DC Medicaid Coverage for Vaginal Estradiol

DC Medicaid (administered through the Department of Health Care Finance under the DC Healthy Families and Alliance programs) covers vaginal estradiol for GSM, but it requires prior authorization (PA) in most cases. The PA requirement means your prescriber must document the diagnosis (ICD-10 N95.2 for atrophic vaginitis, or N95.3) and confirm that lower-cost options were considered or that a specific dose form is medically necessary.

How to Get Prior Authorization Approved

Approval is faster when the clinical note includes:

1. A documented GSM diagnosis with symptom severity (vaginal pH above 5.0, maturation index, or patient-reported dyspareunia).
2. Confirmation that systemic HRT is not preferred because the patient's concern is localized vaginal symptoms only.
3. The specific NDC code for the requested product.

The Endocrine Society's 2022 Menopause Guideline states: "Local (vaginal) estrogen therapy is appropriate for women with genitourinary symptoms of menopause who prefer a localized route or for whom systemic therapy is not indicated." [3] Citing that guideline language directly in the PA letter often accelerates approval.

Formulary Tier and Step Therapy

DC Medicaid managed care plans (AmeriHealth Caritas DC, MedStar Family Choice DC) typically place generic estradiol vaginal cream on Tier 2 and Vagifem on Tier 3. Step therapy may require a trial of a lubricant or generic cream before the brand tablet is approved. Generic estradiol vaginal cream (0.01%, 42.5 g) is the lowest-cost covered option and is therapeutically equivalent to Estrace per the FDA's Orange Book. [4]

Compounded Vaginal Estradiol in DC: Legality and Cost

Compounded vaginal estradiol is legal in the District of Columbia when prepared by a pharmacy holding a valid DC Board of Pharmacy license and operating as a 503A compounder under the Drug Quality and Security Act of 2013 (DQSA). [5] The pharmacy must compound on a patient-specific prescription basis rather than in large batches for office stock.

What 503A Means for DC Patients

A 503A pharmacy compounds for individual patients on a per-script basis. It is not FDA-approved in the same sense as a commercial drug, but it is not illegal. The FDA's guidance on compounding clarifies that 503A pharmacies may prepare estradiol preparations not commercially available in the exact strength or base a prescriber needs, provided the base active ingredient (estradiol USP) is on the FDA's list of approved bulk substances for compounding. [6]

Common compounded formulations requested in DC include:

• Estradiol 0.025 mg/g vaginal cream (lower than the commercial 0.1 mg/g Estrace, used for ultra-low-dose protocols).
• Estradiol 0.5 mg vaginal suppository in a cocoa-butter or polyethylene glycol base.
• Combined estriol/estradiol preparations (sometimes requested, though estriol alone is not FDA-approved for vaginal use in the US).

Cost from a DC-area 503A compounding pharmacy typically runs $25, $60 per month, depending on formulation and base. Some telehealth platforms include the compounding fee in a monthly membership, effectively reducing patient cost to near $0 after the membership fee.

Systemic Absorption Is Low, but Prescribers Still Assess Safety

A key reason many clinicians prefer vaginal estradiol over systemic HRT for isolated GSM is minimal systemic absorption. Serum estradiol from a 10 mcg vaginal tablet stays within or near the postmenopausal reference range (<20 pg/mL) after several weeks of use, unlike the 0.1 mg/g cream at full dose, which can produce measurable systemic levels. [2] This distinction matters when a patient has a history of hormone-sensitive conditions and her oncologist or cardiologist has restricted systemic estrogen. The North American Menopause Society (NAMS) position statement supports low-dose vaginal estrogen use in breast cancer survivors on aromatase inhibitors when non-hormonal options have failed, though shared decision-making with the oncology team is required. [7]

Insurance Coverage Beyond Medicaid

Commercial Plans in DC

Most commercial plans sold on the DC Health Link marketplace (the ACA exchange) cover at least one vaginal estradiol product, typically the generic cream, at Tier 2. Plans from CareFirst BlueCross BlueShield DC and Kaiser Permanente Mid-Atlantic are the two largest issuers. Both list generic estradiol vaginal cream with a Tier 2 copay ranging from $10, $45 per 30-day supply depending on plan design.

Brand-only products (Estring, Vagifem) are more commonly placed on Tier 3 or Tier 4. A non-preferred brand tier copay in DC averages $60, $100 per fill. If your plan requires Tier 3, ask your prescriber to submit a medical exception citing the specific clinical reason the brand formulation is preferred (e.g., patient cannot tolerate cream applicator due to pelvic floor disorder, or tablet preferred for adherence after prior cream treatment failure).

The Women's Health and Cancer Rights Act does not specifically mandate hormone therapy coverage, but the ACA requires non-grandfathered plans to cover preventive services with no cost-sharing under USPSTF A/B recommendations. The USPSTF does not currently carry an A or B recommendation for menopausal hormone therapy for GSM specifically, so cost-sharing applies. [8]

Medicare Part D in DC

Vaginal estradiol is covered under Medicare Part D (not Part B) because it is a self-administered drug. The Low Income Subsidy (LIS/Extra Help) program can reduce the Part D copay to $4.50 or $11.20 per fill (2026 standard LIS amounts) for eligible DC residents. [9] DC residents who are dual-eligible (Medicare and Medicaid) receive LIS automatically.

Telehealth Prescribing of Vaginal Estradiol in DC

Telehealth prescribing is permitted in DC for vaginal estradiol. DC law allows controlled substance prescribing via telemedicine for established patient relationships, and while estradiol is not a controlled substance under the DEA schedule, DC follows the same telehealth practice standards: synchronous audio-video consultation satisfies the prescribing standard of care, and asynchronous-only platforms carry higher regulatory risk. [10]

What a DC Telehealth Visit for Vaginal Estradiol Includes

A compliant DC telehealth visit for GSM should include:

• Symptom assessment (Vulvovaginal Symptom Questionnaire or DIVA questionnaire score).
• Review of personal and family history of breast, uterine, or ovarian cancer.
• Blood pressure and BMI documentation (usually patient-reported at home).
• Discussion of dose form, frequency, and expected time to symptom relief (most patients report improvement within 4 to 8 weeks of consistent twice-weekly use). [2]

No pelvic exam is strictly required before initiating low-dose vaginal estradiol for GSM in a patient with a clearly documented symptom history, per NAMS 2022 guidance, though it is preferred if accessible. [7]

HealthRX Telehealth Access in DC

HealthRX serves DC residents via licensed DC practitioners. Visits are conducted over HIPAA-compliant video. If compounded vaginal estradiol is appropriate, prescriptions are routed to a licensed DC 503A pharmacy with home delivery. Pricing information is available at booking.

Discount Programs and Savings Cards Available to DC Residents

Manufacturer Savings Cards

Pfizer (Vagifem) and other brand manufacturers offer savings cards that can reduce out-of-pocket cost to as low as $0 for commercially insured patients. These cards are not valid for government-insured patients (Medicaid, Medicare, CHIP, TRICARE). The Vagifem savings card, as of 2026, caps the patient's copay at $0 for up to 12 fills for eligible patients. Check the brand's official patient assistance page for current terms, as card terms reset annually.

GoodRx and RxSaver in DC Pharmacies

At CVS (multiple DC locations), Walgreens (Georgetown, Capitol Hill), and Giant Food pharmacies in DC, GoodRx prices for generic estradiol vaginal cream 0.01% run approximately $90, $125 per tube. Yuvafem 10 mcg (18-pack) runs approximately $85, $115. These prices fluctuate weekly based on pharmacy contract negotiations, so check in real time before filling. [11]

DC Pharmaceutical Assistance Program

DC operates the DC Pharmaceutical Assistance Program for the Elderly (DCPAP) for DC residents aged 65 or older with income at or below 300% of the federal poverty level who do not qualify for Medicare Part D Low Income Subsidy. DCPAP can pay the gap between a Medicare Part D copay and the patient's ability to pay. Enrollment is handled through the DC Office on Aging. [12]

The table below is an original HealthRX cost-navigation framework for DC patients, created by the HealthRX clinical team to summarize the decision path by insurance status. No competitor source publishes this decision logic in structured form.

HealthRX DC Vaginal Estradiol Cost Navigation Framework (2026)

| Patient Insurance Status | First Step | Expected Monthly Cost | |---|---|---| | No insurance, income <200% FPL | Apply for DC Medicaid (immediate enrollment available) | $0 after PA approval | | No insurance, income 200 to 400% FPL | GoodRx + generic cream at Giant or CVS | $90, $125 | | No insurance, any income | 503A compounding pharmacy via telehealth platform | $25, $60 | | Commercial insurance (CareFirst, Kaiser) | Check formulary tier; use brand savings card if Tier 3+ | $0, $45 | | Medicare Part D, LIS-eligible | Auto-enrolled in Extra Help; fill at preferred pharmacy | $4.50, $11.20 | | Medicare Part D, not LIS-eligible | Request formulary exception for brand if generic fails | $30, $80 | | DC Medicaid (Healthy Families) | PA submission with GSM diagnosis documentation | $0 | | Dual-eligible (Medicare + Medicaid) | Part D LIS covers gap; no additional action needed | $0 |

Clinical Effectiveness: Why This Drug Is Prescribed

Vaginal estradiol is the standard pharmacologic treatment for genitourinary syndrome of menopause, a condition affecting up to 50% of postmenopausal women. [7] GSM causes vaginal dryness, dyspareunia, urinary urgency, and recurrent urinary tract infections as estrogen withdrawal leads to thinning and decreased lubrication of urogenital tissues.

Evidence Base

The 2016 Cochrane systematic review (Lethaby et al., 30 trials, N=6,235) found local estrogen preparations significantly reduced vaginal dryness (standardized mean difference of 0.73 compared with placebo, P<0.001) and dyspareunia, with no significant difference in efficacy between cream, ring, or tablet at equivalent estradiol doses. [2]

A separate randomized controlled trial published in Menopause (Simon et al., N=309) compared the 10 mcg vaginal tablet to placebo over 12 weeks and found a statistically significant improvement in the Most Bothersome Symptom score at week 12 (P<0.001 vs. Placebo). [13]

Safety Profile for Low-Dose Vaginal Estradiol

Endometrial safety data for low-dose vaginal estradiol are reassuring. A 52-week trial (N=727) of the 4 mcg vaginal insert (Imvexxy, a newer low-dose option) found endometrial hyperplasia rates of 0%, no cases, compared with 0% in placebo, confirming that progestogen co-administration is not required for women using low-dose vaginal estradiol with an intact uterus, per current NAMS guidance. [7] The FDA prescribing label for low-dose vaginal tablets notes that progestogen addition is not recommended for these formulations.

Systemic estradiol levels after the 10 mcg tablet remain within the postmenopausal range. A pharmacokinetic study found mean serum estradiol of 8.8 pg/mL after 12 weeks of twice-weekly use, well below the threshold associated with systemic estrogenic effects. [14]

How to Start Vaginal Estradiol in DC: A Step-by-Step Path

Getting started involves four steps regardless of insurance status.

Step 1: Get a Diagnosis and Prescription

A DC-licensed clinician (physician, NP, or PA with prescribing authority) must write the prescription. This can occur in person at a DC OB-GYN or primary care office, or via a telehealth platform serving DC. The visit typically takes 20 to 30 minutes. Bring a list of current medications, any history of hormone-sensitive cancers, and your insurance card.

Step 2: Confirm Your Coverage Before the Pharmacist Runs It

Call your plan's member services line and ask: "Is estradiol vaginal cream on formulary, what tier, and is there step therapy or PA required?" This prevents a surprise $280 bill at the counter.

Step 3: Apply Cost-Reduction Tools

If covered commercially: check if a manufacturer savings card lowers your copay below your plan copay. If uninsured or underinsured: run GoodRx at your preferred DC pharmacy and compare to the 503A compounding option. If on DC Medicaid: confirm your prescriber is submitting the PA before the prescription is sent.

Step 4: Set Up a Maintenance Routine

Standard maintenance dosing after the initial 2-week daily induction phase is twice weekly (e.g., Sunday and Wednesday). Consistent twice-weekly dosing maintains vaginal tissue health at lower cumulative estradiol exposure than daily use. Most patients notice reduced dryness within 3 to 4 weeks and peak benefit by 8 to 12 weeks. [2]

Frequently Asked Questions